EcoDrugPlus

Tubulin Beta-2a Chain-Like

Ensembl ID : ENSAPOG00000022652
Gene Symbol: LOC110966660
3 Cross references
301 Possible Orthologues:

Tubulin Beta-4b Chain

Ensembl ID : ENSAPOG00000009210
Gene Symbol: LOC110956278
2 Cross references
182 Possible Orthologues:

Tumor Protein P53

Ensembl ID : ENSAPOG00000012386
Gene Symbol: TP53
3 Cross references
231 Possible Orthologues:

Type-2 Angiotensin Ii Receptor-Like

Ensembl ID : ENSAPOG00000007857
Gene Symbol: LOC110958580
3 Cross references
189 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSAPOG00000013144
Gene Symbol: LOC110971262
3 Cross references
203 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSAPOG00000003332
Gene Symbol: TYR
4 Cross references
196 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSAPOG00000013175
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSAPOG00000017242
Gene Symbol: TYK2
3 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSAPOG00000001999
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSAPOG00000006349
Gene Symbol: LOC110949409
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSAPOG00000001890
Gene Symbol: LOC110958734
3 Cross references
198 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSAPOG00000020852
Gene Symbol: LOC110949553
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).